Objective: to investigate the clinical safety and efficacy of intravenous thrombolysis with alteplase in the treatment of acute mild ischemic stroke. Methods: a total of 92 patients with acute mild ischemic stroke adm...Objective: to investigate the clinical safety and efficacy of intravenous thrombolysis with alteplase in the treatment of acute mild ischemic stroke. Methods: a total of 92 patients with acute mild ischemic stroke admitted from September in 2019 to March in 2020 were selected and divided into control group and observation group, with 46 cases in each group. The control group received conventional treatment, and the observation group received intravenous thrombolytic therapy with alteplase. The neurological function deficit, therapeutic effect and safety of the two groups were compared. Results: Before treatment, there was no statistical difference in NIHSS scores between 2 groups (P > 0.05). After treatment, the scores of both groups decreased, and the NIHSS scores of the observation group at different stages decreased more than that of the control group, with statistical significance (P < 0.05). The effective rate of observation group was significantly higher than control group. The complication rate of the observation group was lower than that of the control group. Conclusion: intravenous thrombolysis with alteplase is effective in treating acute mild ischemic stroke. It can be seen that the neurological function deficit has been significantly improved, with fewer complications. It is a treatment method with guaranteed safety and effectiveness, which is worthy of clinical promotion.展开更多
文摘Objective: to investigate the clinical safety and efficacy of intravenous thrombolysis with alteplase in the treatment of acute mild ischemic stroke. Methods: a total of 92 patients with acute mild ischemic stroke admitted from September in 2019 to March in 2020 were selected and divided into control group and observation group, with 46 cases in each group. The control group received conventional treatment, and the observation group received intravenous thrombolytic therapy with alteplase. The neurological function deficit, therapeutic effect and safety of the two groups were compared. Results: Before treatment, there was no statistical difference in NIHSS scores between 2 groups (P > 0.05). After treatment, the scores of both groups decreased, and the NIHSS scores of the observation group at different stages decreased more than that of the control group, with statistical significance (P < 0.05). The effective rate of observation group was significantly higher than control group. The complication rate of the observation group was lower than that of the control group. Conclusion: intravenous thrombolysis with alteplase is effective in treating acute mild ischemic stroke. It can be seen that the neurological function deficit has been significantly improved, with fewer complications. It is a treatment method with guaranteed safety and effectiveness, which is worthy of clinical promotion.
